Next, we investigated whether silencing of PIG3 expression may modulate the sensitivity of NSCLC cells to docetaxel, a well-established anti-mitotic chemotherapeutic drug that is used to treat advanced NSCLC [18]. Here, TP53I3 is linked to non-small cell lung carcinoma.